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Macrophage infiltration and activation in metabolic
tissues underlie obesity-induced insulin resistance
and type 2 diabetes. While inflammatory activation
of resident hepatic macrophages potentiates insulin
resistance, the functions of alternatively activated
Kupffer cells in metabolic disease remain unknown.
Here we show that in response to the Th2 cytokine
interleukin-4 (IL-4), peroxisomeproliferator-activated
receptor d (PPARd) directs expression of the alterna-
tive phenotype in Kupffer cells and adipose tissue
macrophages of leanmice. However, adoptive trans-
fer of PPARd/ (Ppard/) bone marrow into wild-
typemice diminishes alternative activation of hepatic
macrophages, causing hepatic dysfunction and sys-
temic insulin resistance. Suppression of hepatic oxi-
dative metabolism is recapitulated by treatment of
primary hepatocytes with conditioned medium from
PPARd/ macrophages, indicating direct involve-
ment of Kupffer cells in liver lipid metabolism. Taken
together, these data suggest an unexpected benefi-
cial role for alternatively activated Kupffer cells in
metabolic syndrome and type 2 diabetes.
INTRODUCTION
Chronic inflammation is causally linked to obesity, insulin resis-
tance, and type 2 diabetes (Hotamisligil, 2006; Shoelson et al.,
2006). Increased adiposity promotes macrophage infiltration
into adipose tissue (Weisberg et al., 2003; Xu et al., 2003), perpet-
uating local inflammation and causing insulin resistance (Kamei
et al., 2006; Kanda et al., 2006; Weisberg et al., 2006). However,
not all adipose tissuemacrophages (ATMs) exhibit the inflamma-
tory phenotype. For instance, macrophages resident in the adi-
pose tissue of lean animals are alternatively activated and have
decreased inflammatory potential (Lumeng et al., 2007; Ode-496 Cell Metabolism 7, 496–507, June 2008 ª2008 Elsevier Inc.gaard et al., 2007a). Consistent with this observation, we have re-
cently shown that alternatively activated ATMs exert beneficial
effects during times of caloric excess. Specifically, the absence
of alternatively activated ATMs, as in macrophage-specific per-
oxisome proliferator-activated receptor g null (Mac-PPARg/)
mice, promotes mitochondrial dysfunction, leading to obesity
and insulin resistance (Odegaard et al., 2007a).While these stud-
ies have elucidated antidiabetic activities of alternatively acti-
vated ATMs in metabolic syndrome, the functions of these cells
in other metabolic tissues remain poorly understood.
Inflammatory activation of Kupffer cells, the resident macro-
phages in liver, has been implicated in both obesity-induced in-
sulin resistance and fatty liver disease. Genetic ablation of IkB
kinase b (IKKb), an upstream kinase required for activation of nu-
clear factor kB (NF-kB), in myeloid cells reduces macrophage-
mediated inflammation and improves systemic and hepatic
insulin sensitivity (Arkan et al., 2005). Conversely, inflammatory
activation of Kupffer cells by lipopolysaccharide (LPS) promotes
hepatotoxicity in obese mice (Li and Diehl, 2003). While these
and other studies have delineated the pathogenic activities of in-
flammatory Kupffer cells, resident hepatic macrophages display
tremendous plasticity in their activation programs, ranging from
the proinflammatory classical state to the anti-inflammatory
alternative state (Gordon, 2003; Herbert et al., 2004). Despite
the great therapeutic potential of alternatively activated Kupffer
cells, their functions in metabolic disease remain enigmatic.
PPARs, members of the nuclear receptor superfamily (Chawla
et al., 2001), control systemic fatty acidmetabolism by transcrip-
tional activation of target genes (Evans et al., 2004; Kliewer et al.,
2001). Since a variety of fatty acids and fatty acid metabolites
can bind and activate these receptors (Xu et al., 1999), PPARs
act as fatty acid sensors to alter metabolic pathways in response
to changes in fuel availability (Kliewer et al., 2001). Surprisingly,
in alternatively activated murine macrophages, PPARg is re-
quired for mitochondrial biogenesis and b-oxidation of fatty
acids (Odegaard et al., 2007a). Despite an absolute requirement
for oxidative metabolism in alternative macrophage activation
(Vats et al., 2006), macrophage-specific disruption of PPARg
primarily affects alternative activation of ATMs, while sparing
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Alternative Activation of Kupffer Cells by PPARdKupffer cells (Odegaard et al., 2007a). This observation suggests
that distinct transcriptional regulators and signaling pathways
control depot-specific maturation of alternatively activated mac-
rophages; however, the identity of these factors is unknown.
In response to interleukin-4 (IL-4), macrophages enact a coor-
dinated program of oxidative metabolism andmitochondrial bio-
genesis necessary for alternative macrophage activation (Vats
et al., 2006). One critical feature of this metabolic switch is the
substantial increase in fatty acid influx. Because fatty acids and
fatty acid-enriched lipoproteins can transcriptionally activate
the nuclear receptor PPARd in macrophages (Chawla et al.,
2003; Evans et al., 2004; Xu et al., 1999), we investigated its func-
tions in alternative macrophage activation. We report here that
PPARd is absolutely required for full expression of the effector
phenotype of alternatively activatedmacrophages.Genetic dele-
tion of PPARd (Ppard) in bonemarrow cells not only impairs alter-
native activation of tissue macrophages but also predisposes
animals to the development of insulin resistance and metabolic
syndrome. Surprisingly, PPARd deficiency has minimal impact
on ATM biology. In contrast, Kupffer cells deficient in PPARd dis-
play marked impairment in alternative activation, resulting in he-
patic dysfunction and insulin resistance. Together, our findings
identify an unexpected role for PPARd in Kupffer cell biology,
Figure 1. PPARd Regulates Expression of
Arginase 1 in Alternatively ActivatedMacro-
phages
(A–C) Decreased levels of arginase 1 (Arg1) mRNA
(A), protein (B), and enzymatic activity (C) in IL-4-
stimulated PPARd/ (Ppard/) bone marrow-
derived macrophages (BMDMs).
(D) Activation of theArg1 promoter by PPARd/RXR
heterodimers and IL-4. Deletion of the PPAR re-
sponse element in the arginase 1 enhancer abol-
ishes transcriptional activation by PPARd and IL-4.
(E and F) Attenuated induction of arginase 1 in
PPARd/g double-knockout macrophages.
(E)Real-timeanalysisofPPARdandPPARgexpres-
sion in BMDMs generated from control, macro-
phage-specific PPARd/ (Mac-PPARd/), and
Mac-PPARd/g/ mice. Primers specific for exon
4 of PPARd or exon 1 of PPARgwere used to quan-
tify excisionefficiency inBMDMs.ND,notdetected.
(F) qRT-PCR analysis of Arg1mRNA in various ge-
notypes.
Data are presented as mean ± SEM. *p < 0.05;
**p < 0.01.
thereby delineating a molecular mecha-
nism by which this receptor and alterna-
tively activated macrophages ameliorate
obesity-induced insulin resistance.
RESULTS
PPARd Regulates Arginase 1
Expression in Alternatively
Activated Macrophages
To understand the role of PPARd in alter-
native macrophage activation, bone
marrow-derived macrophages (BMDMs)
from wild-type and PPARd-deficient mice were stimulated with
IL-4 for 48–72 hr, a time period that promotes maximal expres-
sion of the alternatively activated phenotype (Munder et al.,
1999). Notably, induction of mRNA and protein for arginase 1
(Arg1), a signature gene induced during alternative macrophage
activation (Gordon, 2003),wasdramatically reduced inPPARd/
macrophages (Figures 1A and 1B). Consistent with impaired
induction of arginase 1, cytosolic arginase activity was reduced
by 75% in PPARd/ macrophages (Figure 1C). To assess
whether PPARd can directly regulate arginase 1, transient trans-
fections were performed with the arginase 1 reporter construct
containing the identified PPAR response element (Odegaard
et al., 2007a; Pauleau et al., 2004). Strikingly, cotransfection of
PPARd greatly augmented IL-4’s transcriptional activity on this
promoter (4-fold), which was not further potentiated by
GW501516, a synthetic agonist of PPARd (Oliver et al., 2001)
(Figure 1D). However, deletion of the PPAR binding site com-
pletely abolished the ability of IL-4 and PPARd to activate this
promoter (Figure 1D), indicating that PPARd regulates arginase
1 in alternatively activated macrophages via this site.
We have previously shown that macrophage-specific PPARg
plays an essential role in the regulation of arginase 1 expression
during alternative macrophage activation (Odegaard et al.,Cell Metabolism 7, 496–507, June 2008 ª2008 Elsevier Inc. 497
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Alternative Activation of Kupffer Cells by PPARdFigure 2. PPARd Is Required for Expression of the Immune Phenotype of Alternative Macrophage Activation
(A) Decreased expression of markers of alternative activation in IL-4-stimulated PPARd/ BMDMs. Relative expression of alternative activation mRNAs was
quantified by qRT-PCR. Retnla, resistin-like a; Mrc1, mannose receptor; Chi3l3, chitinase 3-like 3; Pdcd1lg2, programmed cell death 1 ligand 2.
(B and C) PPARd is required for suppression of IL-6 (B) and IL-12 (C) production in alternatively activated BMDMs.
(D) PPARd is required for the mitogenic response to IL-4 in BMDMs.
Data are presented as mean ± SEM. *p < 0.05; **p < 0.01.2007a). Since our current data also indicate a requirement for
PPARd in the regulation of this facet of alternative activation,
we next investigated the hierarchical relationship between these
two nuclear receptors. For these experiments, we generated
BMDMs from control (PPARdflox/flox), Mac-PPARd/
(PPARdflox/flox;LysMCre), and Mac-PPARd/g/ (PPARd/gflox/flox;
LysMCre) mice, strains recently generated in the laboratory on
the C57BL/6J background (Figure 1E). As shown in Figure 1F,
IL-4 failed to stimulate Arg1 mRNA expression in macrophages
deficient in both PPARg and d, indicating that both nuclear re-
ceptors are required for optimal expression of this gene during
alternative macrophage activation.
PPARd Regulates Immunologic Phenotype
of Alternatively Activated Macrophages
To further evaluate the requirement of PPARd in expression of
the alternative phenotype, we examined other characteristics
of alternative activation in PPARd/ macrophages. As shown
in Figure 2A, IL-4 failed to inducemRNAs encodingRetnla (resis-
tin-like a), Mrc1 (mannose receptor), Chi3l3 (chitinase 3-like 3),
and Pdcd1lg2 (programmed cell death 1 ligand 2) in PPARd/
macrophages (Gordon, 2003; Loke and Allison, 2003; Raes
et al., 2002). This was further substantiated by markedly lower
cell surface expression of dectin-1 (Clec7a) andmannose recep-498 Cell Metabolism 7, 496–507, June 2008 ª2008 Elsevier Inc.tor in PPARd/macrophages (see Figure S1A available online).
Supporting a critical role for PPARd in alternative macrophage
activation, macrophages deficient in PPARdwere also refractory
to IL-13-mediated alternative activation (Figure S2).
Because treatment of macrophages with IL-4 dampens their
inflammatory response (Herbert et al., 2004; Odegaard et al.,
2007b), we next investigated whether PPARd was also required
for this facet of alternative activation. In a dose-dependent man-
ner, pretreatment with IL-4 suppressed LPS-induced secretion
of the inflammatory cytokines IL-6 and IL-12 in wild-type, but
not PPARd/, macrophages (Figures 2B and 2C). Consistent
with a global decrement in the acquisition of the alternative phe-
notype, macrophages lacking PPARd had a markedly lower
mitogenic response to IL-4 as assessed by incorporation of
[3H]thymidine (Figure 2D). Lastly, in support of the central role
of PPARd and g in acquisition of the alternative phenotype, com-
parative analyses of BMDMs from control, Mac-PPARd/, and
Mac-PPARd/g/mice revealed that both receptors are required
for optimal alternative macrophage activation (Figure S3). Taken
together with our previous findings, these results suggest that
both PPARd and PPARg coordinate the macrophage’s tran-
scriptional response to the Th2 cytokines IL-4 and IL-13. PPARg
primarily regulates metabolic programs in alternatively activated
macrophages (Odegaard et al., 2007a), whereas PPARd is
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Alternative Activation of Kupffer Cells by PPARdFigure 3. Conjugated Oleic Acid Potentiates Alternative Macrophage Activation
(A) Oleic acid potentiates IL-4 induction of arginase activity in wild-type, but not PPARd/, BMDMs.
(B–E) PPARd is required for potentiation of alternative activation by oleic acid. BMDMs from 129/SvJ wild-type and PPARd/mice were stimulated with IL-4 for
48 hr in the presence of BSA or BSA:oleic acid conjugate. qRT-PCR analyses were performed on mRNAs for Arg1 (B), Clec7a (dectin-1) (C), Pdcd1lg2 (D), and
Chi3l3 (E).
Data are presented as mean ± SEM. *p < 0.05; **p < 0.01.required for the full expression of their immune phenotype, in-
cluding expression of pattern recognition receptors (Mrc1 and
Clec7a) and costimulatory molecules (Pdcd1lg2) and suppres-
sion of macrophage inflammatory response.
To further explore whether PPARd ligands can initiate or
potentiate alternative macrophage activation, we treated wild-
type macrophages with PPARd activators under three different
experimental settings. First, to determine whether PPARd activa-
tion can induce a Th2 bias in an elicited macrophage population,
wild-type mice were injected intraperitoneally (i.p.) with vehicle
or the synthetic PPARd agonist GW0742 for 5 days (Graham
et al., 2005), and markers of alternative activation were quanti-
fied in biogel-elicited macrophages. As shown in Figure S4A,
GW0742 treatment led to a dramatic increase in the expression
of signature genes for alternative macrophage activation. Sec-
ond, to determine whether chronic treatment with PPARd
agonist induces an alternative bias in BMDMs, wild-type bone
marrow progenitor cells were treated with the PPARd agonist
GW501516 (100 nM) for 7 days. Consistent with the Th2-polar-
izing effects of PPARd in macrophages, stimulation with
GW501516 induced markers of alternative activation in BMDMs
(Figure S4B). Lastly, to explore whether PPARd agonist can syn-
ergize with Th2 cytokines in promoting alternative macrophage
activation, wild-type BMDMs were stimulated with vehicle, IL-4
(2 ng/ml), GW501516 (100 nM), or a combination of IL-4 (2 ng/ml)
and GW501516 (100 nM). As shown in Figure S4C, BMDMs
costimulated with IL-4 and GW501516 had markedly higherlevels of transcripts encoding alternative activation signature
genes. In aggregate, these data suggest that synthetic li-
gands for PPARd can work alone or in combination with en-
dogenous Th2 signals to promote an alternative bias in mac-
rophage activation.
Unsaturated Fatty Acids Potentiate Alternative
Macrophage Activation via PPARd
Tissue macrophages, specifically those present in liver and adi-
pose tissue, are exposed to high levels of fatty acids. Because
a large influx of fatty acids accompanies alternative macrophage
activation, we reasoned that these incoming fatty acids might
activate PPARd, a genetic sensor of fatty acids (Chawla et al.,
2001; Evans et al., 2004). To test this hypothesis, BMDMs
were stimulated with varying doses of IL-4 in the presence of bo-
vine serum albumin (BSA) or BSA conjugated to 100 mM oleic
acid. As shown in Figure 3A, BSA:oleic acid conjugate syner-
gized with IL-4 to induce arginase activity in macrophages.
Notably, this synergistic effect of oleic acid was completely abol-
ished in macrophages lacking PPARd, indicating that monoun-
saturated fatty acids might potentiate the broader program of
alternative activation. Indeed, oleic acid enhanced alternative
macrophage activation in a PPARd-dependent manner as evi-
denced by the induction of Arg1, Clec7a, Pdcd1lg2, and Chi3l3
mRNAs (Figures 3B–3E). Taken together with recent findings of
Shi et al. (2006), these data indicate that local availability of fatty
acids can alter the activation potential of macrophages. WhileCell Metabolism 7, 496–507, June 2008 ª2008 Elsevier Inc. 499
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Alternative Activation of Kupffer Cells by PPARdsaturated fatty acids, such as lauric and palmitic acids, ligate
toll-like receptor 4 (TLR4) to promote proinflammatory activation
of macrophages (Kim et al., 2007; Shi et al., 2006), monounsat-
urated fatty acids enhance expression of the anti-inflammatory
alternative state by activating the nuclear receptor PPARd.
PPARd Is Required for Alternative Activation
of Resident Macrophages
To verify whether PPARd is essential for alternative activation of
resident macrophages, we analyzed macrophage signatures in
metabolic tissues of leanmice. As expected, the signature genes
of alternatively activated macrophages, including Clec7a,
Retnla, Tgfb1, Jag1, and Mrc1, were dramatically reduced in
white adipose tissue (WAT) of PPARd/mice (Figure S5A). Sur-
prisingly, genetic deletion of PPARd also impaired alternative ac-
tivation of hepatic macrophages, the Kupffer cells, as evidenced
by decreased expression of Arg1, Clec7a, Jag1, Pdcd1lg2, and
Chia mRNAs (Figure S5B). Furthermore, treatment of lean wild-
type mice with GW0742, a highly selective agonist for PPARd,
increased expression of alternative macrophage activation
markers in both WAT and liver (Figures S5C and S5D). Thus, in
contrast to PPARg (Odegaard et al., 2007a), PPARd transcrip-
tional signaling is required for the maintenance of alternative
activation of ATMs and Kupffer cells in lean mice.
Hematopoietic PPARd Protects against Diet-Induced
Insulin Resistance
Having established that PPARd regulates the immune program of
alternativemacrophage activation,we investigatedwhethermice
lacking PPARd in the macrophage compartment were at an
increased risk of developing metabolic syndrome. To conduct
these experiments, we adoptively transferred wild-type and
PPARd-deficient bone marrow into lethally irradiated wild-type
animals (Weisberg et al., 2003). After reconstitution for 4 weeks,
age-matched cohorts were placed on a high-fat diet (HFD) for
22 weeks to promote maximal infiltration of macrophages into
WAT (Xu et al., 2003). qPCR analysis of genomic DNA confirmed
>99% replacement of wild-type marrow by PPARd/ cells
(Figure S6A). Importantly, in this time frame, even the relatively ra-
dioresistant Kupffer cells are replaced with new cells from the
bone marrow (Figures S6B and S6D) (Kennedy and Abkowitz,
1997).Moreover, isolation of F4/80 (Emr1)-positivemacrophages
from WAT and liver confirmed that a majority of tissues macro-
phageswerederived fromPPARd/hematopoietic cells (Figures
S6C and S6D). Remarkably, reconstitution of wild-typemice with
PPARd/ bone marrow (PPARd/ BMT) led to development of
glucose intolerance on HFD (Figure 4A). In addition, compared
to mice transplanted with wild-type bone marrow (WT BMT),
PPARd/ BMT mice were more resistant to glucose lowering
by exogenous insulin (Figure 4B). Consistent with this decrease
in insulin sensitivity, fasting insulin levels were 2-fold higher in
PPARd/BMTmice (Figure 4C).However, fasting levels of circu-
lating lipids were not significantly different between the two co-
horts of transplantedmice (Table S1). To identify the sites of insu-
lin resistance, WT BMT and PPARd/ BMT mice were injected
with insulin via their inferior vena cava, and tissues were quickly
harvested for biochemical analyses of insulin signaling (Arkan
et al., 2005; Cai et al., 2005). As shown in Figures 4D–4F, phos-
phorylation of Akt was markedly reduced in liver, quadriceps,500 Cell Metabolism 7, 496–507, June 2008 ª2008 Elsevier Inc.and WAT of PPARd/ BMT mice, indicating onset of global in-
sulin resistance. Since reduction in oxidative phosphorylation
(OXPHOS) is causally linked to development of insulin resistance
in mice and humans (Mootha et al., 2003; Patti et al., 2003;
Petersen et al., 2003; Vianna et al., 2006), we looked for evidence
ofmitochondrialdysfunction inall three tissues.Notably,RT-qPCR
analyses revealed a profound decrease (30%–50%) in expression
of enzymes for fatty acid oxidation (Acox1,Acadm, andAcadl) and
OXPHOS (Ndufs1, Sdhb, Uqcrc1, Cox4i1, and Atp5j) in livers of
PPARd/ BMT mice (Figure 4G). Similarly, genes important in
oxidative metabolism (Acox1 and Cpt1b) and electron transport
(Ndusf1, Uqcrc1, and Cox4i1) were suppressed by 60%–90% in
quadriceps of PPARd/ BMT animals (Figure 4H). Importantly,
in both tissues, expression of transcriptional regulators control-
ling mitochondrial oxidative metabolism (Tfam, Nrf1, Pgc1a,
and Pgc1b) was dramatically reduced (30%–80%). However,
metabolic programs for b-oxidation and OXPHOS were largely
intact in WAT of PPARd/ BMT mice (Figure S7C), suggesting
that hematopoietic PPARd deficiency primarily suppresses
oxidative metabolism in myocytes and hepatocytes.
Hematopoietic PPARd Protects
against Diet-Induced Obesity
We recently demonstrated that alternatively activated ATMs pro-
tect against diet-induced obesity (Odegaard et al., 2007a),
prompting us to evaluate changes in adiposity in PPARd/ chi-
meric animals. At 18 weeks on HFD, dual-energy X-ray absorp-
tiometry (DEXA) indicated that weight-matched PPARd/ BMT
mice had significantly higher fat content (43.4% ± 0.39% versus
37.8% ± 1.81%; p < 0.01) and slightly lower lean body mass
(18.2 ± 0.47 g versus 19.9 ± 0.52 g; p < 0.05) than WT BMT con-
trols (Figure 5A). Furthermore, gross postmortem analyses
showedmarked enlargement of adipose depots (Figure 5B), par-
alleling the 50% increase in epididymal fat pad mass, 7-fold
increase in serum leptin, and 20% reduction in serum adiponec-
tin (Figure 5C; Table S1). However, in contrast to adipocyte cell
size inMac-PPARg/mice (Odegaard et al., 2007a), adipocytes
were significantly larger in PPARd/ BMT mice (Figure 5D;
Figure S7A), suggesting that adipocyte hypertrophy likely ac-
counts for the increase in total adiposity. Because adipocyte
morphology is markedly different in these two models, we next
quantified ATM content and activation. In striking contrast to
Mac-PPARg/mice, ATM content trended toward being higher
in PPARd/ BMT mice without significant change in the signa-
ture of alternatively activated macrophages (Figures 5E and
5F; Figure S7B). Moreover, unlike WAT of Mac-PPARg/
mice, expression analysis of PPARd/ BMT WAT showed only
a modest decrease in adipocyte programs of lipid accretion,
storage, and utilization (Figure S7C), findings that are consistent
with the minor increase in inflammatory response in this tissue
(Figure 5F) (Weisberg et al., 2003). Direct coculture of adipocytes
with macrophages further affirmed that PPARd/macrophages
do not significantly impact adipocyte biology as assessed by
insulin-stimulated glucose uptake (Figure S7D) and expression
of cytokines and adipokines in these cells (Figure S7E). Together,
these data suggest that nutritional status is a key determinant of
whether PPARd signaling is required for alternative activation
of ATMs. While PPARd signaling is necessary for alternative
activation of ATMs in lean mice (Figure S5A), it is largely
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Alternative Activation of Kupffer Cells by PPARdFigure 4. Hematopoietic Deficiency of PPARd Exacerbates Insulin Resistance and Impairs Glucose Tolerance
(A) Oral glucose tolerance tests (1 g/kg) were carried out after 18 weeks of high-fat diet in male mice reconstituted with wild-type or PPARd/ bone marrow (WT
BMT and PPARd/ BMT, respectively) (n = 5–7 per cohort).
(B) Insulin tolerance tests (0.65 U/kg) were performed in obese mice after a 4 hr fast (n = 5–7 per cohort). Similar results were obtained in two other cohorts of
transplanted mice (n = 7 per group).
(C) Fasting serum levels of insulin in WT BMT and PPARd/ BMT mice after a 5 hr fast.
(D–F) Impairment in insulin action in PPARd/BMTmice. Total cell lysates were immunoblotted for phospho-Akt (pAkt) or total Akt in liver (D), quadricepsmuscle
(E), and epididymal white adipose tissue (WAT) (F).
(G and H) Mitochondrial dysfunction in peripheral tissues of PPARd/ BMT mice. Relative transcript levels for genes encoding key enzymes in b-oxidation and
oxidative phosphorylation (OXPHOS) and transcriptional regulators controlling these pathways in liver (G) and quadriceps (H) are shown.
Data are presented as mean ± SEM. *p < 0.05; **p < 0.01.dispensable for maintenance of this macrophage population in
WAT of obese mice (Figure 5F). Future experiments utilizing re-
cently generatedMac-PPARd/g double-knockout mice will allow
us to determine whether induction of PPARg compensates for
loss of PPARd signaling in ATMs of obese animals. Nonetheless,
the lack of significant macrophage phenotype in WAT of
PPARd/ BMT mice suggests potential involvement of alterna-
tively activated macrophages in other metabolic tissues.
Alternative Activation of Kupffer Cells Preserves
Hepatic Function
Kupffer cells in lean PPARd/mice exhibited diminished capac-
ity for alternative activation (Figure S5B), prompting us to exam-ine the number and activation state of hepatic macrophages in
obese animals. Although HFD feeding led to a modest increase
(20%) in hepatic macrophage content in PPARd/ BMT
mice (Figures S8A and S8B), the activation state of resident ma-
crophages was dramatically different between WT BMT and
PPARd/ BMT mice. Notably, the signature of alternatively
activated Kupffer cells was greatly reduced in livers of obese
PPARd/ BMT mice (Figure 6A). Furthermore, liver arginase
activity was also reduced by 41% in PPARd/ BMT mice
(Figure 6B), confirming that resident macrophages were gradu-
ally being replaced by cells derived from the bone marrow (Fig-
ures S6C and S6E). To ascertain whether PPARd is required
for IL-4-mediated alternative activation of Kupffer cells,Cell Metabolism 7, 496–507, June 2008 ª2008 Elsevier Inc. 501
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Alternative Activation of Kupffer Cells by PPARdFigure 5. Increased Adiposity in PPARd/ BMT Mice
(A) Body composition was quantified by dual-energy X-ray absorptiometry (DEXA) in weight-matched transplanted mice (n = 7 per cohort).
(B) Representative images of necropsied WT BMT and PPARd/ BMT mice after 22 weeks of high-fat diet.
(C) Increased epididymal fat pad mass in PPARd/ BMT mice (n = 5 per cohort).
(D) Increased adipocyte cell size in PPARd/ BMT mice. Adipocyte cell size was measured using dark-field images.
(E and F) Macrophage content and activation in WAT.
(E) Adipose tissue macrophage (ATM) content was determined by immunostaining for the macrophage antigen F4/80. p = 0.16 by paired t test; n = 4 per cohort.
(F) Interrogation of ATM activation state by qRT-PCR. Emr1, F4/80;Cd68, macrosialin; Jag1, jagged 1; Il1rn, IL-1 receptor antagonist; Il4ra, IL-4 receptor a;Nos2,
inducible nitric oxide synthase; Tnfa, tumor necrosis factor a; Il6, interleukin-6.
Data are presented as mean ± SEM. *p < 0.05; **p < 0.01.wild-type and PPARd/mice were challenged with IL-4 and the
activation state of Kupffer cells was interrogated by qRT-PCR.
Remarkably, injection of IL-4 induced the expression of the alter-
native activation signature genes Arg1, Clec7a, Chi3l3, and
Tgfb1 in a PPARd-dependent manner (Figure 6C), thus proving
an absolute requirement for PPARd in the IL-4-driven program
of Kupffer cell alternative activation.
We have previously shown that impairment in alternative mac-
rophage activation is linked to development of mitochondrial
dysfunction in metabolic tissues (Odegaard et al., 2007a). That
PPARd/ chimeric mice have markedly reduced expression of
b-oxidation and OXPHOS genes in liver (Figures 4G) suggests
that alternatively activated Kupffer cells might directly modulate
hepatic metabolism. To test this hypothesis, b-oxidation of fatty
acids was analyzed in wild-type primary hepatocytes that had
been cocultured with wild-type or PPARd/ BMDMs for 72 hr.
Strikingly, hepatocytes cocultured with PPARd/macrophages
exhibited an 25% decrease in the rate of fatty acid oxidation
compared to those cocultured with wild-type macrophages
(Figure S8C). Furthermore, qRT-PCR analyses of cocultured pri-
mary hepatocytes demonstrated potent suppression of b-oxi-
dation and OXPHOS pathways by PPARd/ macrophages502 Cell Metabolism 7, 496–507, June 2008 ª2008 Elsevier Inc.(Figure S8D). Since similar results were obtained when primary
hepatocytes were treated with conditioned medium (CM) from
wild-type or PPARd/ macrophages (Figures 6D and 6E), this
suggests that factors secreted by macrophages can directly
modulate oxidative metabolism in parenchymal cells. Finally,
confirming a causal relationship between PPARd-deficient
Kupffer cells and dysregulation of hepatic metabolism, livers of
PPARd/ BMT mice exhibited gross and histological evidence
of hepatic steatosis (Figure 5B and Figure 6F) and had an
50% increase in extractable liver triglycerides (Figure 6G).
DISCUSSION
The infiltration and activation of macrophages in metabolic tis-
sues are key events in the pathogenesis of diet-induced obesity
and insulin resistance (Qatanani and Lazar, 2007). However,
most metabolic tissues, including adipose tissue and liver,
contain a resident population of less inflammatory, alternatively
activated macrophages (Gordon, 2003) whose functions in obe-
sity-induced metabolic disease remain poorly understood. To
address this critical question, we have taken a systematic
approach to identify transcriptional regulators that control the
Cell Metabolism
Alternative Activation of Kupffer Cells by PPARdFigure 6. Impaired Alternative Activation of Kupffer Cells and Hepatic Dysfunction in PPARd/ BMT Mice
(A) Decreased expression of signature genes for alternative activation of macrophages in PPARd/ BMT livers (n = 5–7 per cohort).
(B) Reduction in liver arginase activity in PPARd/ BMT mice (n = 5–7 per cohort).
(C) IL-4 is unable to induce alternative activation of Kupffer cells in PPARd/ mice (n = 4 per cohort). Tgfb1, transforming growth factor b1.
(D and E) Treatment of primary hepatocytes with macrophage conditioned medium (CM) alters their oxidative metabolism. CM from PPARd/ macrophages
suppresses oxidative metabolism as monitored by b-oxidation of fatty acids (D) and expression of fatty acid oxidation and OXPHOS genes (E).
(F and G) Histologic (F) and biochemical (G) evidence of increased triglyceride accumulation in livers of PPARd/ BMT mice.
Data are presented as mean ± SEM. *p < 0.05; **p < 0.01.maturation of alternatively activated macrophages in tissues.
Previously, we demonstrated that PPARg orchestrates the pro-
gram of oxidative metabolism in alternatively activated macro-
phages, a requisite for alternativematuration of ATMs (Odegaard
et al., 2007a). In contrast, we now show that PPARd coordinates
the immune phenotype of alternatively activated macrophages,
both in vitro and in vivo. Interestingly, hematopoietic deficiency
of PPARd selectively impairs alternative activation of Kupffer
cells in obese mice, leading to reduction in oxidative metabolism
and insulin sensitivity. Furthermore, direct coculture of primary
hepatocytes with PPARd/macrophages recapitulates the liver
phenotype of PPARd/ BMTmice. Taken together, our findings
suggest that PPARd and PPARg control distinct aspects of alter-native macrophage activation to ameliorate obesity-induced
insulin resistance (Figure 7).
While inflammatory activation of Kupffer cells by bacterial by-
products induces hepatic insulin resistance (Arkan et al., 2005; Li
and Diehl, 2003), the role of alternatively activated Kupffer cells in
liver metabolism has remained enigmatic. Unexpectedly, we
found that the PPARd-regulated program of Kupffer cell alterna-
tive activation mediates beneficial effects on metabolic disease,
an observation that is supported by three independent lines of
evidence. First, in lean animals, genetic deletion of PPARd
reduces the expression of genes that constitute the signature
of alternatively activated Kupffer cells. Second, transplantation
of PPARd/ bone marrow into wild-type mice diminishesCell Metabolism 7, 496–507, June 2008 ª2008 Elsevier Inc. 503
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dysfunction and insulin resistance in hepatocytes. Third, direct
coculture of PPARd/ macrophages with primary hepatocytes
leads to dramatic suppression of oxidative metabolism in the
parenchymal cells. Lastly, since Kupffer cell replacement in
PPARd/ BMT mice is incomplete (Figure S6D), our studies
likely underestimate the metabolic benefits of the alternatively
activated Kupffer cells.
Extensive metabolic characterization of PPARd/ BMT and
Mac-PPARg/ mice revealed that the activation state of resi-
dent macrophages plays an integral role in regulation of periph-
eral metabolism (Figure 7). For instance, inMac-PPARg/mice,
loss of alternatively activated ATMs causes impairment in adipo-
cyte function, resulting in reduced oxidative metabolism and
insulin sensitivity (Hevener et al., 2007; Odegaard et al.,
2007a). Similarly, Kupffer cells in PPARd/ BMT mice have
diminished capacity to undergo alternative activation, leading
to a dramatic reduction in OXPHOS and insulin sensitivity.
Hence, these findings suggest that, irrespective of their sites of
residence, alternatively activated macrophages have a profound
influence on oxidative metabolism and lipid homeostasis in
peripheral tissues. Interestingly, the maturation of alternatively
activated macrophages is itself regulated by fatty acids and their
cognate receptors, PPARg and PPARd, thereby positioning
these cells to be the cellular integrators of lipid metabolism. In
support of this idea, saturated fatty acids (the ‘‘bad’’ fats) bind
and activate TLR4 signaling in macrophages, thereby increasing
adipose tissue inflammation and insulin resistance (Kim et al.,
2007; Shi et al., 2006). In contrast, monounsaturated fatty acids
Figure 7. Model Highlighting the Metabolic Functions of Alterna-
tively Activated Macrophages
PPARg transcriptional signaling is required for maturation of macrophages in
adipose tissue, whereas PPARd controls the expression of the alternative phe-
notype in Kupffer cells of obese mice. Two potential mechanisms by which al-
ternatively activated macrophages may improve insulin action in obese mice
are (1) paracrine inhibition of inflammation and (2) secretion of trophic factors
that can directly modulate oxidative metabolism in parenchymal cells (small
arrows).504 Cell Metabolism 7, 496–507, June 2008 ª2008 Elsevier Inc.(the ‘‘good’’ fats) activate PPARd to bias tissue macrophages to
the alternative state, thus improving insulin sensitivity. However,
the precise molecular mechanisms by which alternatively acti-
vated macrophages modulate insulin action and peripheral
metabolism remain unclear. On the one hand, attenuation of tis-
sue inflammation by paracrine actions of these cells might lead
to improvement in insulin signaling (Bouhlel et al., 2007). On
the other hand, alternatively activated macrophages might se-
crete trophic factors that act in a paracrine or endocrine manner
to enhance oxidative metabolism in peripheral tissues (Figure 7).
Experimental support for either hypothesis will require further
investigation.
While our findings demonstrate a role for alternatively acti-
vated ATMs and Kupffer cells in lipid homeostasis, the stimuli
driving this program ofmacrophage activation and the regulation
thereof remain unclear. In addition to the Th2 cytokines IL-4 and
IL-13, the microenvironment of tissue macrophages might con-
tain other stimuli that support alternative activation (Rauh et al.,
2005). In this study, we provide evidence that one such signal
is likely to be the composition of fatty acids to which the macro-
phage is exposed. For instance, monounsaturated fatty acids
activate PPARd to enhance maturation of alternatively activated
macrophages in tissues, suggesting that an increase in cytosolic
concentration of free fatty acids might promote alternative mac-
rophage activation and improve insulin action. In support of this
notion, deletion or inhibition of cytosolic fatty acid-binding pro-
teins improves insulin sensitivity (Furuhashi et al., 2007; Hotami-
sligil et al., 1996); however, the potential involvement of fatty
acid-binding proteins in alternative macrophage activation will
require further investigation.
Although our findings suggest subtype specificity for PPARs in
acquisition of the metabolic and immune phenotypes of alterna-
tively activatedmacrophages, it remains unknownwhether phar-
macologic activation of either receptor can rescue the observed
defects in single-receptor knockout macrophages. For instance,
it will be important to determine whether treatment of PPARd/
macrophages with synthetic activators of PPARg can compen-
sate for absence of PPARd signaling. Thus, these types of
gain-of-function experiments will be carried out using macro-
phages deficient in PPARg, PPARd, or both PPARg and PPARd.
In summary, we have demonstrated a critical role for alterna-
tively activated Kupffer cells in metabolic syndrome. In the ab-
sence of PPARd, Kupffer cells are unable to maintain the alterna-
tive phenotype, leading to suppression of oxidative metabolism
and worsening of insulin resistance in peripheral tissues. Since
our findings indicate that macrophage activation plays a critical
role when caloric intake exceeds expenditure, cellular targeting
of Kupffer cells to undergo alternative activation might be an
effective strategy for treating obesity and insulin resistance.
EXPERIMENTAL PROCEDURES
In Vivo Metabolic Analyses
PPARd/ mice used in these studies were generated by the R.M. Evans lab-
oratory and backcrossed onto the 129/SvJ strain for eight generations (Barak
et al., 2002). 129/SvJ mice were used as wild-type controls for these experi-
ments. All in vivo studies were initiated at 8–12 weeks of age. For bonemarrow
transplant studies, whole bone marrow was prepared from wild-type and
PPARd/mice and injected intravenously (53 106 cells/recipient) into lethally
irradiated (850 rad) wild-type recipients. After 2–4 weeks of rest for bone
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Alternative Activation of Kupffer Cells by PPARdmarrow reconstitution, mice were fed a high-fat diet (Bio-Serv F3283) for
18–25 weeks to promote obesity. DEXA was performed using a PIXImus II
(GE Healthcare). Oral glucose tolerance tests (1 g/kg) were performed after a
14 hr fast. For insulin tolerance tests,micewere challengedwith an i.p. injection
of human insulin (0.65 U/kg) after a 4 hr fast. For biochemical analysis of insulin
signaling, human insulin (5 U/kg) was injected into the inferior vena cava after
a 4 hr fast. Liver and quadricepswere isolated and snap frozen in liquid nitrogen
at 2 and 5 min, respectively. Tissue homogenates were immunoblotted for
total Akt and phospho-Akt (Ser473) (Cell Signaling). Adipocyte cell size analy-
sis and ATM quantification were performed as described previously (Ode-
gaard et al., 2007a). Serum levels of lipids (total cholesterol and triglycerides),
cytokines (TNFa, IL-6, and IL-1b), adipokines (leptin, resistin, and adiponectin),
and insulin in fasted mice were quantified using commercially available kits.
For liver triglyceride quantification, samples were finely minced and extracted
overnight in acetone at 4C. Extractable lipid content was measured using
a commercially available kit (Stanbio) (Qu et al., 2006). To activate Kupffer cells
with IL-4, mice were injected with IL-4 complexed with anti-IL-4 antibody,
a procedure that has been shown to extend the half-life of this cytokine in vivo
(Finkelman et al., 1993). Briefly, soluble complexes of IL-4 (2 mg) with anti-IL-4
antibody (BVD4-11, 10 mg) were injected i.p. into recipient mice on day 1 and
day 4, and livers were harvested on day 5 for qRT-PCR analysis.
Quantitative RT-PCR Analyses
Gene expression analyseswere performed as described previously (Odegaard
et al., 2007a, 2007b). Briefly, total RNAwas extracted from homogenized sam-
ples using TRIzol reagent (Invitrogen) and used as a template for cDNA synthe-
sis (Marligen). Real-time quantitative PCR assays were carried in triplicate
using DNA Engine Opticon 2. Relative expression levels of mRNAswere calcu-
lated by the comparative threshold cycle method using L32 (Rpl32) as an inter-
nal control. All primer sequences were verified by BLASTing against the NCBI
mouse genome sequence database to ensure specificity.
In Vitro Macrophage Activation Analyses
BMDMs were cultured from wild-type and PPARd/ 129/SvJ as described
previously (Odegaard et al., 2007a). Cells were stimulated with recombinant
mIL-4 (10 ng/ml) or mIL-13 (10–40 ng/ml) for 48–72 hr in low-glucose medium
(1 g/l). Arginase activity was measured by colorimetrically monitoring the evo-
lution of urea from arginine (Rutschman et al., 2001). To assess cytokine pro-
duction, cells were pretreated with IL-4 for 24–48 hr with subsequent stimula-
tion with LPS (5 ng/ml). Secreted cytokines were quantified by ELISA per the
manufacturer’s protocols (BD Pharmingen). Cellular proliferation was as-
sessed by measuring [3H]thymidine incorporation over a 16 hr pulse. For the
oleic acid experiments, low-glucose medium was supplemented with fatty
acid-free BSA (0.35%, Roche) and filter sterilized. Oleic acid (100 mM, Sigma)
was added to the medium and allowed to equilibrate for 4–5 hr at 37C with
periodic mixing. Subsequently, differentiated BMDMs were switched to
BSA-containing medium and simultaneously stimulated with IL-4 for 24–48 hr.
All experiments were repeated independently at least three times.
Immunoblotting and Flow Cytometry
Total cellular proteins were subjected to electrophoresis and immunoblotted
for arginase 1 (BD Biosciences) (Rauh et al., 2005). For flow cytometry,
BMDMs were treated with vehicle or IL-4 (10 ng/ml) for 48–72 hr, harvested
in PBS, and resuspended in PBS containing 2% FCS and 0.2 mM EDTA. Mac-
rophages were blocked with 200 mg/ml normal mIgG, stained with antibodies
directed against dectin-1 or mannose receptor, and analyzed on a FACSCali-
bur system.
Transient Transfections
Transient transfection experiments were carried out as described previously
(Vats et al., 2006). Briefly, plasmid DNAs were introduced into RAW264.7 cells
by electroporation (300V, 1000 mF), and cells were allowed to recover for 2 hr in
macrophage serum-free medium (Invitrogen). Luciferase activity was quanti-
fied 16 hr after stimulation with IL-4 (10 ng/ml) or GW501516 (100 nM) using
a dual-luciferase reporter assay kit (Biotium). All experiments were performed
in triplicate and repeated at least three times.Macrophage-Hepatocyte Coculture
Primary hepatocytes were isolated and cultured using Invitrogen liver media
and reagents. Briefly, the livers of anesthetized 8- to 12-week-old wild-type
mice were sequentially perfusedwith liver perfusion and digest media via cath-
eterization of the inferior vena cava. Digested livers were then resected and
dissociated in liver wash buffer. Hepatocytes were purified over 50% Percoll
and allowed to recover overnight on collagen-coated plates in Hepatozyme
serum-free medium. Wild-type and PPARd/ BMDMs were seeded onto he-
patocyte cultures at a 1:10 ratio and cocultured for a further 72 hr. Fatty acid
oxidation assays were performed using a sodium hydroxide trap in a modified
tissue culture flask (Vats et al., 2006). Parallel coculture plates were assayed
for gene expression by qRT-PCR. Similarly, fatty acid oxidation and hepatic
gene expression were assessed in primary hepatocytes 72 hr after treatment
with wild-type or PPARd/ macrophage conditioned medium. All experi-
ments were repeated independently at least three times.
Macrophage-Adipocyte Coculture
3T3-L1 cells were differentiated as described previously (Lumeng et al., 2007).
On day 10, wild-type and PPARd/BMDMswere seeded onto adipocyte cul-
tures to an approximate density of 1:10 and cultured in macrophage medium
for 48 hr. For glucose uptake, cultures were washed and stimulated with insulin
(100 nM) or medium alone; glucose uptake was subsequently measured as
described previously (Odegaard et al., 2007a).
Isolation of Tissue Macrophages from Transplanted Mice
Kupffer cell-enriched and stromal vascular fractions were isolated from livers
and adipose tissue of transplanted mice as described previously (Weisberg
et al., 2003). Macrophages present in these fractions were subsequently
isolated using F4/80-coupled Dynabeads (Invitrogen) per the manufacturer’s
protocol. qRT-PCR analyses were performed for F4/80 and the region
encompassing exon 4 of PPARd, which is absent in PPARd/ cells.
PPARd Ligand Studies
For in vivo analyses, wild-type 129/SvJ mice were given i.p. injections of vehi-
cle or GW0742 (20 mg/kg/day) for 5 days (Graham et al., 2005). Twenty-four
hours after the first injection, 1 ml of biogel beads suspended in sterile PBS
was injected into the peritoneal cavity. Four days later, elicited macrophages
were isolated by peritoneal lavage and subjected to qRT-PCR analyses. Sim-
ilarly, the activation state of Kupffer cells and ATMs was determined in mice
after treatment with vehicle or GW0742 for 5 days (n = 3–4 per treatment).
For in vitro analyses, bone marrow cells from wild-type 129/SvJ mice were
treated with GW501516 (100 nM) for 7 days, with medium changes every
2 days. To assess whether PPARd ligands can synergize with IL-4 to promote
alternative macrophage activation, BMDMs from 129/SvJ wild-typemice were
prestimulated with low-dose IL-4 (2 ng/ml) for 24 hr followed by treatment with
GW501516 for an additional 24 hr.
Statistical Analyses
Data are presented as mean ± SEM. All p values were calculated using two-
tailed distribution, two-sample unequal variance Student’s t test. *p < 0.05;
**p < 0.01.
SUPPLEMENTAL DATA
Supplemental Data include one table and eight figures and can be found with
this article online at http://www.cellmetabolism.org/cgi/content/full/7/6/496/
DC1/.
ACKNOWLEDGMENTS
We thank members of the Chawla laboratory and A. Loh for valuable com-
ments and P. Murray for providing key reagents. This work was supported
by grants from the NIH (DK076760 and HL076746), Rockefeller Brothers
Fund (Goldman Philanthropic Partnerships), and the American Diabetes Asso-
ciation to A.C. A.C. is a Charles E. CulpeperMedical Scholar. Support was pro-
vided by the Stanford Medical Scientist Training Program (J.I.O. and A.R.E.),
the American Heart Association (J.I.O.), an HHMI Gilliam Fellowship (A.R.E.),Cell Metabolism 7, 496–507, June 2008 ª2008 Elsevier Inc. 505
Cell Metabolism
Alternative Activation of Kupffer Cells by PPARdand National Research Service Award AI066402 (R.R.R.-G.). All animal care
was in accordance with Stanford University’s A-PLAC committee guidelines.
Received: October 11, 2007
Revised: February 28, 2008
Accepted: April 1, 2008
Published: June 3, 2008
REFERENCES
Arkan, M.C., Hevener, A.L., Greten, F.R., Maeda, S., Li, Z.W., Long, J.M.,
Wynshaw-Boris, A., Poli, G., Olefsky, J., and Karin, M. (2005). IKK-beta links
inflammation to obesity-induced insulin resistance. Nat. Med. 11, 191–198.
Barak, Y., Liao, D., He, W., Ong, E.S., Nelson, M.C., Olefsky, J.M., Boland, R.,
and Evans, R.M. (2002). Effects of peroxisome proliferator-activated receptor
delta on placentation, adiposity, and colorectal cancer. Proc. Natl. Acad. Sci.
USA 99, 303–308.
Bouhlel, M.A., Derudas, B., Rigamonti, E., Dievart, R., Brozek, J., Haulon, S.,
Zawadzki, C., Jude, B., Torpier, G., Marx, N., et al. (2007). PPARgamma acti-
vation primes humanmonocytes into alternativeM2macrophages with anti-in-
flammatory properties. Cell Metab. 6, 137–143.
Cai, D., Yuan, M., Frantz, D.F., Melendez, P.A., Hansen, L., Lee, J., and Shoe-
lson, S.E. (2005). Local and systemic insulin resistance resulting from hepatic
activation of IKK-beta and NF-kappaB. Nat. Med. 11, 183–190.
Chawla, A., Repa, J.J., Evans, R.M., and Mangelsdorf, D.J. (2001). Nuclear re-
ceptors and lipid physiology: opening the X-files. Science 294, 1866–1870.
Chawla, A., Lee, C., Barak, Y., He, W., Rosenfeld, J., Liao, D., Han, J., Kang,
H., and Evans, R. (2003). PPAR delta is a very low-density lipoprotein sensor
in macrophages. Proc. Natl. Acad. Sci. USA 100, 1268–1273.
Evans, R.M., Barish, G.D., and Wang, Y.-X. (2004). PPARs and the complex
journey to obesity. Nat. Med. 10, 355–361.
Finkelman, F.D., Madden, K.B., Morris, S.C., Holmes, J.M., Boiani, N., Katona,
I.M., andMaliszewski, C.R. (1993). Anti-cytokine antibodies as carrier proteins.
Prolongation of in vivo effects of exogenous cytokines by injection of cytokine-
anti-cytokine antibody complexes. J. Immunol. 151, 1235–1244.
Furuhashi, M., Tuncman, G., Gorgun, C.Z., Makowski, L., Atsumi, G., Vaillan-
court, E., Kono, K., Babaev, V.R., Fazio, S., Linton, M.F., et al. (2007). Treat-
ment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein
aP2. Nature 447, 959–965.
Gordon, S. (2003). Alternative activation of macrophages. Nat. Rev. Immunol.
3, 23–35.
Graham, T.L., Mookherjee, C., Suckling, K.E., Palmer, C.N., and Patel, L.
(2005). The PPARdelta agonist GW0742X reduces atherosclerosis in
LDLR/ mice. Atherosclerosis 181, 29–37.
Herbert, D.R., Holscher, C., Mohrs, M., Arendse, B., Schwegmann, A., Rad-
wanska, M., Leeto, M., Kirsch, R., Hall, P., Mossmann, H., et al. (2004). Alter-
native macrophage activation is essential for survival during schistosomiasis
and downmodulates T helper 1 responses and immunopathology. Immunity
20, 623–635.
Hevener, A.L., Olefsky, J.M., Reichart, D., Nguyen, M.T., Bandyopadyhay, G.,
Leung, H.Y.,Watt, M.J., Benner, C., Febbraio, M.A., Nguyen, A.K., et al. (2007).
Macrophage PPAR gamma is required for normal skeletal muscle and hepatic
insulin sensitivity and full antidiabetic effects of thiazolidinediones. J. Clin.
Invest. 117, 1658–1669.
Hotamisligil, G.S. (2006). Inflammation and metabolic disorders. Nature 444,
860–867.
Hotamisligil, G.S., Johnson, R.S., Distel, R.J., Ellis, R., Papaioannou, V.E., and
Spiegelman, B.M. (1996). Uncoupling of obesity from insulin resistance
through a targeted mutation in aP2, the adipocyte fatty acid binding protein.
Science 274, 1377–1379.
Kamei, N., Tobe, K., Suzuki, R., Ohsugi, M., Watanabe, T., Kubota, N., Oht-
suka-Kowatari, N., Kumagai, K., Sakamoto, K., Kobayashi, M., et al. (2006).
Overexpression of monocyte chemoattractant protein-1 in adipose tissues
causes macrophage recruitment and insulin resistance. J. Biol. Chem. 281,
26602–26614.506 Cell Metabolism 7, 496–507, June 2008 ª2008 Elsevier Inc.Kanda, H., Tateya, S., Tamori, Y., Kotani, K., Hiasa, K., Kitazawa, R., Kitazawa,
S., Miyachi, H., Maeda, S., Egashira, K., and Kasuga, M. (2006). MCP-1 con-
tributes to macrophage infiltration into adipose tissue, insulin resistance, and
hepatic steatosis in obesity. J. Clin. Invest. 116, 1494–1505.
Kennedy, D.W., and Abkowitz, J.L. (1997). Kinetics of central nervous system
microglial and macrophage engraftment: analysis using a transgenic bone
marrow transplantation model. Blood 90, 986–993.
Kim, F., Pham, M., Luttrell, I., Bannerman, D.D., Tupper, J., Thaler, J., Hawn,
T.R., Raines, E.W., and Schwartz, M.W. (2007). Toll-like receptor-4 mediates
vascular inflammation and insulin resistance in diet-induced obesity. Circ.
Res. 100, 1589–1596.
Kliewer, S.A., Xu, H.E., Lambert, M.H., and Willson, T.M. (2001). Peroxisome
proliferator-activated receptors: from genes to physiology. Recent Prog.
Horm. Res. 56, 239–263.
Li, Z., and Diehl, A.M. (2003). Innate immunity in the liver. Curr. Opin. Gastro-
enterol. 19, 565–571.
Loke, P., and Allison, J.P. (2003). PD-L1 and PD-L2 are differentially regulated
by Th1 and Th2 cells. Proc. Natl. Acad. Sci. USA 100, 5336–5341.
Lumeng, C.N., Bodzin, J.L., and Saltiel, A.R. (2007). Obesity induces a pheno-
typic switch in adipose tissue macrophage polarization. J. Clin. Invest. 117,
175–184.
Mootha, V.K., Lindgren, C.M., Eriksson, K.F., Subramanian, A., Sihag, S.,
Lehar, J., Puigserver, P., Carlsson, E., Ridderstrale, M., Laurila, E., et al.
(2003). PGC-1alpha-responsive genes involved in oxidative phosphorylation
are coordinately downregulated in human diabetes. Nat. Genet. 34, 267–273.
Munder, M., Eichmann, K., Moran, J.M., Centeno, F., Soler, G., and Modolell,
M. (1999). Th1/Th2-regulated expression of arginase isoforms in murine mac-
rophages and dendritic cells. J. Immunol. 163, 3771–3777.
Odegaard, J.I., Ricardo-Gonzalez, R.R., Goforth, M.H., Morel, C.R., Subrama-
nian, V., Mukundan, L., Eagle, A.R., Vats, D., Brombacher, F., Ferrante, A.W.,
and Chawla, A. (2007a). Macrophage-specific PPARgamma controls alterna-
tive activation and improves insulin resistance. Nature 447, 1116–1120.
Odegaard, J.I., Vats, D., Zhang, L., Ricardo-Gonzalez, R., Smith, K.L., Sykes,
D.B., Kamps, M.P., and Chawla, A. (2007b). Quantitative expansion of ES cell-
derived myeloid progenitors capable of differentiating into macrophages. J.
Leukoc. Biol. 81, 711–719.
Oliver,W.R., Jr., Shenk, J.L., Snaith,M.R., Russell, C.S., Plunket, K.D., Bodkin,
N.L., Lewis, M.C., Winegar, D.A., Sznaidman, M.L., Lambert, M.H., et al.
(2001). A selective peroxisome proliferator-activated receptor delta agonist
promotes reverse cholesterol transport. Proc. Natl. Acad. Sci. USA 98,
5306–5311.
Patti, M.E., Butte, A.J., Crunkhorn, S., Cusi, K., Berria, R., Kashyap, S.,
Miyazaki, Y., Kohane, I., Costello, M., Saccone, R., et al. (2003). Coordi-
nated reduction of genes of oxidative metabolism in humans with insulin resis-
tance and diabetes: Potential role of PGC1 and NRF1. Proc. Natl. Acad. Sci.
USA 100, 8466–8471.
Pauleau, A.L., Rutschman, R., Lang, R., Pernis, A., Watowich, S.S., and Mur-
ray, P.J. (2004). Enhancer-mediated control of macrophage-specific arginase I
expression. J. Immunol. 172, 7565–7573.
Petersen, K.F., Befroy, D., Dufour, S., Dziura, J., Ariyan, C., Rothman, D.L., Di-
Pietro, L., Cline, G.W., and Shulman, G.I. (2003). Mitochondrial dysfunction in
the elderly: possible role in insulin resistance. Science 300, 1140–1142.
Qatanani, M., and Lazar, M.A. (2007). Mechanisms of obesity-associated insu-
lin resistance: many choices on the menu. Genes Dev. 21, 1443–1455.
Qu, S., Altomonte, J., Perdomo, G., He, J., Fan, Y., Kamagate, A., Meseck, M.,
and Dong, H.H. (2006). Aberrant Forkhead box O1 function is associated with
impaired hepatic metabolism. Endocrinology 147, 5641–5652.
Raes, G., De Baetselier, P., Noel, W., Beschin, A., Brombacher, F., and Has-
sanzadeh Gh, G. (2002). Differential expression of FIZZ1 and Ym1 in alterna-
tively versus classically activated macrophages. J. Leukoc. Biol. 71, 597–602.
Rauh, M.J., Ho, V., Pereira, C., Sham, A., Sly, L.M., Lam, V., Huxham, L., Min-
chinton, A.I., Mui, A., and Krystal, G. (2005). SHIP represses the generation of
alternatively activated macrophages. Immunity 23, 361–374.
Cell Metabolism
Alternative Activation of Kupffer Cells by PPARdRutschman, R., Lang, R., Hesse, M., Ihle, J.N., Wynn, T.A., and Murray, P.J.
(2001). Cutting edge: Stat6-dependent substrate depletion regulates nitric ox-
ide production. J. Immunol. 166, 2173–2177.
Shi, H., Kokoeva, M.V., Inouye, K., Tzameli, I., Yin, H., and Flier, J.S. (2006).
TLR4 links innate immunity and fatty acid-induced insulin resistance. J. Clin.
Invest. 116, 3015–3025.
Shoelson, S.E., Lee, J., and Goldfine, A.B. (2006). Inflammation and insulin re-
sistance. J. Clin. Invest. 116, 1793–1801.
Vats, D., Mukundan, L., Odegaard, J.I., Zhang, L., Smith, K.L., Morel, C.R.,
Greaves, D.R., Murray, P.J., and Chawla, A. (2006). Oxidative metabolism
and PGC-1beta attenuate macrophage-mediated inflammation. Cell Metab.
4, 13–24.
Vianna, C.R., Huntgeburth, M., Coppari, R., Choi, C.S., Lin, J., Krauss, S., Bar-
batelli, G., Tzameli, I., Kim, Y.B., Cinti, S., et al. (2006). Hypomorphic mutation
of PGC-1beta causes mitochondrial dysfunction and liver insulin resistance.
Cell Metab. 4, 453–464.Weisberg, S.P., McCann, D., Desai, M., Rosenbaum, M., Leibel, R.L., and Fer-
rante, A.W., Jr. (2003). Obesity is associated withmacrophage accumulation in
adipose tissue. J. Clin. Invest. 112, 1796–1808.
Weisberg, S.P., Hunter, D., Huber, R., Lemieux, J., Slaymaker, S., Vaddi, K.,
Charo, I., Leibel, R.L., and Ferrante, A.W., Jr. (2006). CCR2 modulates inflam-
matory and metabolic effects of high-fat feeding. J. Clin. Invest. 116, 115–124.
Xu, H.E., Lambert, M.H., Montana, V.G., Parks, D.J., Blanchard, S.G., Brown,
P.J., Sternbach, D.D., Lehmann, J.M., Wisely, G.B., Willson, T.M., et al. (1999).
Molecular recognition of fatty acids by peroxisome proliferator- activated re-
ceptors. Mol. Cell 3, 397–403.
Xu, H., Barnes, G.T., Yang, Q., Tan, G., Yang, D., Chou, C.J., Sole, J., Nichols,
A., Ross, J.S., Tartaglia, L.A., and Chen, H. (2003). Chronic inflammation in fat
plays a crucial role in the development of obesity-related insulin resistance. J.
Clin. Invest. 112, 1821–1830.Cell Metabolism 7, 496–507, June 2008 ª2008 Elsevier Inc. 507
